Chinese Guidelines for the Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack 2010

CNS Neuroscience and Therapeutics

Volumn 18, Issue 2, 2012, Pages 93-101

  Wang, Yong Jun ^a   Zhang, Su Ming ^b   Zhang, Liqun ^c   Wang, Chun Xue ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Guideline; Ischemic stroke; Prevention; TIA

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOFIBRATE; CLOPIDOGREL; COLESTYRAMINE; DIPYRIDAMOLE; DIURETIC AGENT; EPROSARTAN; GEMFIBROZIL; GLICLAZIDE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; LIPID; NICOTINIC ACID; NITRENDIPINE; TRIFLUSAL; VITAMIN B GROUP; WARFARIN;

ACUTE HEART INFARCTION; ADD ON THERAPY; ANGIOPLASTY; ANTICOAGULATION; ARTERY DISSECTION; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY STENTING; CAROTID ENDARTERECTOMY; CHINA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIET; DISEASE ASSOCIATION; DRUG INDUCED HEADACHE; EMBOLISM; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; MITRAL VALVE DISEASE; MITRAL VALVE PROLAPSE; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATENT FORAMEN OVALE; PRACTICE GUIDELINE; RISK FACTOR; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THROMBUS; TRANSIENT ISCHEMIC ATTACK; VALVULAR HEART DISEASE;

CHINA; HUMANS; ISCHEMIC ATTACK, TRANSIENT; SECONDARY PREVENTION; STROKE;

EID: 84863078754     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2011.00290.x     Document Type: Article

References (48)

1. Guidelines Writing Group of Diagnosis and Treatment for Acute Ischemic Stroke of Cerebrovascular Disease Group of Neurologic Branch of Chinese Medical Association. Chinese guidelines of diagnosis and treatment for acute ischemic stroke 2010. Chin J Neurol 2010;43:146-153.
2. Chinese Guidelines Revision Committee of Prevention and Treatment for Hypertension. Chinese guidelines of prevention and treatment for hypertension (2005 revision edition). Chin J Hypertens 2005;13:5-41.
3. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: A systematic review. Stroke 2003;34: 2741-2748.
4. Diener HC, Sacco R, Yusuf S.;Steering Committee; PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007;23: 368-380.
5. Schrader J, Lüders S, Kulschewski A, et al. MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36: 1218-1226.
6. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: A quantitative overview. Hypertension 2007;50: 181-188.
7. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R.;Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
9. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004;364: 685-696.
10. Collins R, Armitage J, Parish S, Sleigh P, Peto R.;Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003;361: 2005-2016.
11. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: A meta-analysis of randomized trials. Arch Intern Med 2003;163:669-676.
12. Goldstein LB, Amarenco P, Zivin J, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2009;40:3526-3531.
13. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: A meta-analysis involving 121, 000 patients. Am J Med 2008;121:24-33.
14. Guidelines Development Joint Committee of Prevention and Treatment for Dyslipidemia of Chinese Adult. Chinese guidelines of prevention and treatment for dyslipidemia of adults. Chin J Cardiol 2007;35:390-427.
15. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445-453.
16. European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: Interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991;337:1235-1243.
17. Barnett HJ, Taylor DW, Eliasziw M, et al. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998;339:1415-1425.
18. Furie KL, Kasner SE, Adams RJ, et al. American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Clinical Cardiology; and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke 2011;42:227-276.
19. Sacco RL, Adams R, Albers G, et al. American Heart Association/American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Circulation 2006 14;113: e409-e449.
20. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): A randomised trial. Lancet 2001;357:1729-1737.
21. Brahmanandam S, Ding EL, Conte MS, Belkin M, Nguyen LL. Clinical results of carotid artery stenting compared with carotid endarterectomy. J Vasc Surg 2008;47: 343-349.
22. Zaidat OO, Klucznik R, Alexander MJ, et al. NIH Multi-center Wingspan Intracranial Stent Registry Study Group. The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis. Neurology 2008;70: 1518-1524.
23. Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004;CD000l85: 1-15.
24. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324: 71-86.
25. Connolly S, Pogue J, Hart R, et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006;367: 1903-1912.
26. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S.;ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-2078.
27. Hu DY, Zhang HP, Sun YH, Jiang LQ. The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: Warfarin compared with aspirin. Chin J Cardiol 2006;34:295-298.
28. Sun YH, Hu DY. The efficiency and safety of anticoagulation therapy in atrial fibrillation in Chinese. Chin J Intern Med 2004; 43:258-260.
29. Antman EM, Hand M, Armstrong PW, et al. 2004 Writing Committee Members: Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117: 296-329.
30. Silaruks S, Thinkhamrop B, Kiatchoosakun S, Wongvipaporn C, Tatsanavivat P. Resolution of left atrial thrombus after 6 months of anticoagulation in candidates for percutaneous transvenous mitral commissurotomy. Ann Intern Med 2004;140: 101-105.
31. Bonow RO, Carabello BA, Chatterjee K, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;52: e1-142.
32. Khetarpal V, Mahajan N, Madhavan R, et al. Calcific aortic valve and spontaneous embolic stroke: A review of literature. J Neurol Sci 2009;287: 32-35.
33. Vahanian A, Baumgartner H, Bax J, et al. Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007;28:230-268.
34. Massie BM, Collins JF, Ammon SE, et al. WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009;119:1616-1624.
35. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
36. Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354: 1706-1717.
37. Vane JR, Meade TW. Second European Stroke Prevention Study (ESPS 2): Clinical and pharmacological implications. J Neurol Sci 1997;145:123-125.
38. Sacco RL, Diener HC, Yusuf S, et al. PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-1251.
39. Diener HC, Bogousslavsky J, Brass LM, et al. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337.
40. Cruz-Fernández JM, López-Bescós L, García-Dorado D, et al. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 2000;21: 457-465.
41. Huang Y, Cheng Y, Wu J, et al. Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention Cooperation Investigators. Cilostazol as an alternative to aspirin after ischaemic stroke: A randomised, double-blind, pilot study. Lancet Neurol 2008;7:494-499.
42. Mohr JP, Thompson JL, Lazar RM, et al. Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-1451.
43. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305-1316.
44. Menon R, Kerry S, Norris JW, Markus HS. Treatment of cervical artery dissection: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatr 2008;79:1122-1127.
45. Braun MU, Fassbender D, Schoen SP, Haass M, Schraeder R, Scholtz W, Strasser RH. Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J Am Coll Cardiol 2002;39:2019-2025.
46. Lonn E, Yusuf S, Arnold MJ, et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-1577.
47. Bønaa KH, Njølstad I, Ueland PM, et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-1588.
48. Spence JD, Howard VJ, Chambless LE, Malinow MR, Pettigrew LC, Stampfer M, Toole JF. Vitamin Intervention for Stroke Prevention (VISP) trial: Rationale and design. Neuroepidemiology 2001;20:16-25.